The thickness of glomerular basement membrane predicts complete remission in primary membranous nephropathy

References

• Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet. 2015;385(9981):1983–1992.
   PubMed Web of Science ®Google Scholar
• Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Seminars Immunopathology. 2014;36(4):381–397.
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annual Rev Pathol. 2020;15:287–313.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao YJ, Dong QR, et al. Immune-mediated membranous nephropathy: long term fluconazole usage caused podocyte autophagy. J Biochem Mol Toxicol. 2022;36(1):e22935.
   PubMed Web of Science ®Google Scholar
• Nieto-Gañán I, Iturrieta-Zuazo I, Rita C, et al. Revisiting immunological and clinical aspects of membranous nephropathy. Clin Immunol. 2022;237:108976.
   PubMed Web of Science ®Google Scholar
• Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983–997.
   PubMed Web of Science ®Google Scholar
• Beck LH, Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.
   PubMed Web of Science ®Google Scholar
• Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566–574.
   PubMed Web of Science ®Google Scholar
• Reinhard L, Stahl RAK, Hoxha E. Is primary membranous nephropathy a complement mediated disease? Molecular Immunology. 2020;128:195–204.
   PubMed Web of Science ®Google Scholar
• Miner JH. Renal basement membrane components. Kidney Int. 1999;56(6):2016–2024.
   PubMed Web of Science ®Google Scholar
• Miner JH. The glomerular basement membrane. Exp Cell Res. 2012;318(9):973–978.
   PubMed Web of Science ®Google Scholar
• Liu W, Gao C, Liu Z, et al. Idiopathic membranous nephropathy: glomerular pathological pattern caused by extrarenal immunity activity. Front Immunol. 2020;11:1846.
   PubMed Web of Science ®Google Scholar
• Zhang N, Dai H, Dong X, et al. Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time. Front Immunol. 2022;13:926368.
   PubMed Web of Science ®Google Scholar
• Netti GS, Infante B, Spadaccino F, et al. Serum levels of BAFF and APRIL predict clinical response in anti-PLA2R-positive primary membranous nephropathy. J Immunol Res. 2019;2019:8483650.
   Google Scholar
• Liu J, Zha Y, Zhang P, et al. The association between serum complement 4 and kidney disease progression in idiopathic membranous nephropathy: a multicenter retrospective cohort study. Front Immunol. 2022;13:896654.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen S, Li Z, et al. Correlation of body mass index with clinicopathologic parameters in patients with idiopathic membranous nephropathy. DMSO. 2022;ume 15:1897–1909.
   Google Scholar
• Dong L, Li YQ, Guo SM, et al. Hypercholesterolemia correlates with glomerular phospholipase A2 receptor deposit and serum anti-phospholipase A2 receptor antibody and predicts proteinuria outcome in idiopathic membranous nephropathy. Front Immunol. 2022;13:905930.
   PubMed Web of Science ®Google Scholar
• An C, Akankwasa G, Liu J, et al. Urine markers of renal tubular injury in idiopathic membranous nephropathy: a cross sectional study. Clin Chim Acta.. 2019;492:7–11.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Cui Z, Zhang MF, et al. Clinical implications of pathological features of primary membranous nephropathy. BMC Nephrol. 2018;19(1):215.
   PubMedGoogle Scholar
• Wei C, He Y, Li T, et al. Glomerulosclerosis predicts poor renal outcome in patients with idiopathic membranous nephropathy. Int Urol Nephrol. 2021;53(3):505–514.
   PubMedGoogle Scholar
• Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310(15):946–950.
   PubMed Web of Science ®Google Scholar
• Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int. 1992;41(2):428–434.
   PubMed Web of Science ®Google Scholar
• Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006;69(9):1641–1648.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Churg J, Ehrenreich T. Membranous nephropathy. Persp Nephrol Hypertension. 1973;1 Pt1:443–448.
   PubMedGoogle Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779.
   PubMed Web of Science ®Google Scholar
• Canetta PA, Troost JP, Mahoney S, et al. Health-related quality of life in glomerular disease. Kidney Int. 2019;95(5):1209–1224.
   PubMed Web of Science ®Google Scholar
• Lee T, Chung Y, Poulton CJ, et al. Serum albumin at partial remission predicts outcomes in membranous nephropathy. Kidney Int Reports. 2020;5(5):706–717.
   PubMed Web of Science ®Google Scholar
• Lee T, Derebail VK, Kshirsagar AV, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111–1118.
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.
   PubMed Web of Science ®Google Scholar
• Thompson A, Cattran DC, Blank M, et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol. 2015;26(12):2930–2937.
   PubMed Web of Science ®Google Scholar
• Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16(5):1188–1194.
   PubMed Web of Science ®Google Scholar
• Passerini P, Pasquali S, Cesana B, et al. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant 1989;4(6):525–529.
   PubMed Web of Science ®Google Scholar
• Laluck BJ, Jr., Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999;33(6):1026–1032.
   PubMed Web of Science ®Google Scholar
• Horvatic I, Ljubanovic DG, Bulimbasic S, et al. Prognostic significance of glomerular and tubulointerstitial morphometry in idiopathic membranous nephropathy. Pathol Res Pract. 2012;208(11):662–667.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357–1366.
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Beck LH, Jr., Beck DM, et al. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–1291.
   PubMed Web of Science ®Google Scholar
• Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. Clin J Am Soc Nephrol. 2016;11(1):137–154.
   PubMed Web of Science ®Google Scholar
• Motavalli R, Etemadi J, Kahroba H, et al. Immune system-mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets. Life Sci. 2019;238:116923.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Okada K, Matsui Y, et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol Dial Transplant. 2018;33(5):832–840.
   Google Scholar
• Ma H, Sandor DG, Beck LH. Jr. The role of complement in membranous nephropathy. Seminars in Nephrology. 2013;33(6):531–542.
   PubMed Web of Science ®Google Scholar
• Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005;16(5):1195–1204.
   PubMed Web of Science ®Google Scholar
• Ghiggeri GM, Seitz-Polski B, Justino J, et al. Multi-autoantibody signature and clinical outcome in membranous nephropathy. Clin J Am Soc Nephrol. 2020;15(12):1762–1776.
   Google Scholar
• Liu W, Gao C, Dai H, et al. Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role. Front Immunol. 2019;10:1809.
   PubMed Web of Science ®Google Scholar
• Xu X, Nie S, Ding H, et al. Environmental pollution and kidney diseases. Nat Rev Nephrol. 2018;14(5):313–324.
   PubMed Web of Science ®Google Scholar
• Oto OA, Demir E, Mirioglu S, et al. Clinical significance of glomerular C3 deposition in primary membranous nephropathy. J Nephrol. 2021;34(2):581–587.
   PubMed Web of Science ®Google Scholar
• Batsford S, Oite T, Takamiya H, et al. Anionic binding sites in the glomerular basement membrane: possible role in the pathogenesis of immune complex glomerulonephritis. Renal Physiology. 1980;3(1-6):336–340.
   PubMedGoogle Scholar
• Border WA, Kamil ES, Ward HJ, et al. Antigenic changes as a determinant of immune complex localization in the rat glomerulus. Lab Invest. 1981;45(5):442–449.
   PubMed Web of Science ®Google Scholar
• Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. J Am Soc Nephrol. 2017;28(11):3262–3277.
   PubMed Web of Science ®Google Scholar
• Luo J, Yuan Y, Tian J, et al. Clinicopathological characteristics and outcomes of PLA(2)R-Associated membranous nephropathy in seropositive patients without PLA(2)R staining on kidney biopsy. Am J Kidney Dis. 2022;80(3):364–372.
   PubMed Web of Science ®Google Scholar